Figure 4.

Better tumor control of IBI323 treatment in vivo. Tumor growth (a) and survival (b) of MC38 tumor-bearing mice treated with equalmolar amounts of IBI110 (5.0 mg/kg), Bi-127 (2.6 mg/kg), IBI323 (5.8 mg/kg), IgG (5.0 mg/kg) and a relatively lower dose of IBI323 (1 mg/kg). MC38 cells overexpressing human PD-L1 were subcutaneously injected into human PD-L1/LAG-3 knock-in C57BL/6 mice. Mice were treated with indicated antibodies on days 6, 10, 14, 17, and 21 post implantation. (c) Individual tumor volumes in each treatment group on day 21, the last time point when all animals in the study were alive (n ≥ 5 mice/group). (d, e) Tumor growth and body weight change of NOG mice bearing A375 human melanoma tumor which were treated with IgG (11.6 mg/kg) and IBI323 (3.5 mg/kg or 11.6 mg/kg) (n ≥ 5 mice/group). (f) Tumor growth of NOG mice bearing established A375 human melanoma tumor which were treated with IgG, IBI110 + Bi-127 and IBI323 (11.6 mg/kg or 23.2 mg/kg) (n ≥ 5 mice/group). Statistical analysis was done using two-way ANOVA for growth curves, log-rank test for survival curves, and t test for tumor weights